REGENXBIO (RGNX) to Release Earnings on Wednesday

REGENXBIO (NASDAQ:RGNX - Get Free Report) is expected to be announcing its Q1 2025 earnings results before the market opens on Wednesday, May 14th. Analysts expect the company to announce earnings of $0.35 per share and revenue of $105.35 million for the quarter.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.27) by $0.26. The company had revenue of $21.21 million during the quarter, compared to analysts' expectations of $23.70 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. On average, analysts expect REGENXBIO to post $-5 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

REGENXBIO Stock Performance

Shares of NASDAQ RGNX traded up $0.44 during trading hours on Monday, hitting $7.96. The company's stock had a trading volume of 437,182 shares, compared to its average volume of 847,619. The stock has a market cap of $398.93 million, a price-to-earnings ratio of -1.58 and a beta of 1.11. The business has a 50-day simple moving average of $7.32 and a 200-day simple moving average of $8.00. REGENXBIO has a 12 month low of $5.04 and a 12 month high of $16.85.

Wall Street Analysts Forecast Growth

RGNX has been the topic of several recent research reports. Chardan Capital restated a "buy" rating and issued a $52.00 price target on shares of REGENXBIO in a research note on Thursday, March 20th. Leerink Partners set a $24.00 price objective on REGENXBIO in a research note on Tuesday, March 18th. Morgan Stanley raised their price target on REGENXBIO from $22.00 to $24.00 and gave the company an "overweight" rating in a report on Friday, March 14th. Raymond James began coverage on REGENXBIO in a report on Friday, February 7th. They issued an "outperform" rating and a $27.00 target price on the stock. Finally, HC Wainwright cut their target price on REGENXBIO from $36.00 to $34.00 and set a "buy" rating on the stock in a research report on Monday, March 17th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $31.63.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.